Clinical Candidates

Domvanalimab (dom) is an Fc-silent investigational monoclonal antibody that binds to TIGIT and may enable CD155:CD226 interaction and subsequent immune cell activation.

Etrumadenant (etruma) is an investigational small molecule, dual A2A/A2B adenosine receptor antagonist. Quemliclustat (quemli) is an investigational small molecule CD73 inhibitor. Adenosine is an immunosuppressive substance produced inside tumors as a result of rapid cancer cell turnover and, in some cases, in connection with certain antitumor interventions, such as chemotherapy and radiation.

Zimberelimab (zim) is an investigational monoclonal antibody that binds PD-1 and may restore the antitumor activity of T cells.

Casdatifan (cas) is an investigational small molecule inhibitor of the oxygen-sensing transcription factor HIF-2⍺ that has demonstrated potent antitumor activity in xenograft models of renal cell cancer.

AB598 is an investigational humanized Fc-silent IgG1 anti-CD39 antibody that binds to the cell surface of CD39 in the tumor microenvironment to promote anti-tumor immunity.

AB801 is an investigational novel, highly potent and selective small molecule AXL inhibitor with an improved profile in a space with limited advancements.